October, 4th
3D Signatures Sells 2M Shares to ScreenCell for C$500K Info+

3D Signatures Sells 2M Shares to ScreenCell for C$500K

Oct 04, 2017


NEW YORK (GenomeWeb) – Personalized medicine company 3D Signatures announced late yesterday that it has sold 2 million shares of its common stock in a private placement to French biotechnology company ScreenCell for gross proceeds of C$500,000 (US$400,198).

3DS is developing diagnostic and prognostic tests based on a proprietary platform that analyzes the spatial patterns of chromosomes by tagging and imaging their telomeres. The proceeds from the placement, under which the stock was sold for C$.25 per share, will be used primarily to fund 3DS’ clinical operations, including clinical wages and laboratory expenses. The rest will be used for general working capital.

ScreenCell has been working with 3DS since the company was founded and supplies it with a screening system for the capture and isolation of circulating tumor cells from blood.

“It’s a strong endorsement of 3DS when a major supplier and technology collaborator makes a financial investment in the company,” 3DS CEO Jason Flowerday said in a statement. “ScreenCell is a leader in its field and we look forward to a continued partnership.”

In July, the company filed paperwork with Canadian regulators to privately sell up to 12.5 million shares of its common stock in the US for a total of C$5 million.


September, 28th
ScreenCell Establishment Licence Canada MD class 1 Info+

Establishment Licence

Medical Device


10 Avenue Charles Péguy

Centre Roger Pérez

95200 Sarcelles France

This Licence is issued in accordance with the Medical Devices Regulation of Food and Drugs Act for the following activities:

Manufacture Devices for Distribution: CLASS I


canada-4 canada

                             Issue Date: 2016-06-02


November, 2nd
ScreenCell sponsors Molecular Med TRI-CON 2016, March 7-9 2016, San Francisco, CA Info+

March 7 – 9, 2016 | Moscone North Convention Center | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference

Circulating Tumor Cells : Enabling Liquid Biopsy

Monday, March 7
1:15 Luncheon Presentation I:

Size-Based Isolation of Circulating Tumor Cells Associated to Droplet Digital PCR Allow Prediction of KRAS Mutations in Patients with Colorectal Cancer before Tumor Surgery.

Jérôme A. Denis, M.D., Ph.D., Sorbonne Universités, Paris, France



December, 8th
ScreenCell sponsors the CLARA (6th Edition of Industrials-Academics meeting) Lyon, France (December 16, 2014). Info+

November, 5th
ScreenCell sponsors the CIRCULATE (Circulating Cancer Biomarkers) Boston, MA (November 18-20, 2014). Info+

Conference Day One

Tuesday, 18th November

  •  CTC Innovation & Developments: Predictive Uses for CTCs

11.40 Isolation and Characterization of Circulating Melanoma Cancer Cells by Size Filtration and Fluorescent In Situ Hybridization

Masahiko Yanagita, Postdoctoral Fellow, Dana-Farber Cancer Institute


  • Molecular Characterization of CTCs:

2.10 Characterization Of Prostate Cancer CTCs By 3D Nuclear Telomere Imaging

Sabine Mai, Director, Genomic Centre for Research and Diagnosis

CIRCULATE circulating cancer Biomarkers Boston 2014 Agenda

August, 14th
ACTC 2014 2nd International Symposium on Advances in Circulating Tumor Cells October 8th–11th, 2014, Crete, Greece Info+

Detection of Circulating Tumor Cells (CTC) in peripheral blood can serve as a “liquid biopsy” approach and has emerged as one of the hottest fields in cancer research. Nowadays, CTC molecular characterization has a strong potential to be translated into individualized targeted treatments. A variety of analytical systems are continuously been developed for CTC isolation, detection and molecular characterization. CTC molecular characterization at the single cell level holds considerable promise for the identification of therapeutic targets and resistance mechanisms in CTCs as well as for the stratification of patients and real-time monitoring of systemic therapies.

The ACTC meeting is focused on the potential of CTC as a liquid biopsy by bringing together researchers and clinicians to discuss practical implementation of CTCs and translate much of the excellent basic research in this field into clinical practice. The most prominent and established researchers in the field will present state of the art research on the biology of metastasis and on the technical advancements in the isolation, detection and molecular characterization of CTCs. Latest findings on the clinical applications of CTCs in real time monitoring of systemic anticancer therapies will be discussed. A particular emphasis will be given on the relationship of CTCs to cancer stem cells and the relevance of recent findings for the development and use of new targeted therapies in oncology.

August, 14th
Innovation Days 2014 The leading partnering meeting in Open Innovation for Life Sciences Paris • October 6-7, 2014 Info+

Conferences – Exhibition Hall – One-on-one partnering meetings – Networking

Innovation Days brings together public and private actors of the life sciences to maximize business opportunities during two days of high level conferences and one-on-one partnering meetings.

January, 23rd
ScreenCell sponsors CIRCULATE Circulating Cancer Biomarkers, February 18-20 2014, Berlin Info+

February 19th 11.50 am Size-based Technology for Circulating Tumor Cells Isolation: extensive characterization after culture expansion 

Georges Uzan, CSO, ScreenCell

  • Live CTC isolation
  • CTC cytomorphology of Melanoma and Breast Cancer
  • CTC proliferation and invasion

January, 23rd
ScreenCell sponsors Molecular Med TRI-CON, February 9-14 2014, San Francisco Info+

Cancer channel – Circulating Tumor Cells (Spotlight on Clinical Validation)

February 11th 12:00 pm Characterization of Circulating Large Cells Isolated by ScreenCell-Filtration in Renal Tumor Patients
Karoline Lackner, M.D., Professor, Pathology, Institute of Pathology, Medical University of Graz

Circulating non-hematologic cells (CNHCs) – putative CTCs/CTMs – isolated from blood by ScreenCell filtration in 40 patients with renal tumors were characterized. We found that CNHC-clusters with malignant or uncertain malignant cytomorphological features were CD45neg/CD31pos. Array-CGH revealed a balanced genome in 83% of cytomorphologically malignant/uncertain malignant CNHC-clusters whereas 17% showed genomic DNA imbalances not found in the primary tumors. Thus the majority of CNHC-clusters may be of endothelial origin.


November, 13th
JIB 2013 58eme Journées Internationales de Biologie, 13-14-15 Novembre 2013, Paris Info+


1 Biochimie Endocrinienne et Oncologique, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Paris, France ; 2 Chirurgie digestive et hépato-bilio-pancréatique, Hôpitaux Universitaires Pitié-Salpêtrière, Paris, France ; 3 ScreenCell SA, 10 avenue Charles Péguy, Sarcelles, France.


Dans cette étude, nous avons choisi d’évaluer un dispositif commercialisé par lasociété ScreenCell qui permet d’isoler les cellules tumorales circulantes sur le critèrede leurs tailles grâce à un filtre ayant des pores de 7.5 ±0.36 μm. En effet il a été montré que les CTCs avaient une taille moyenne plus importante que les cellules sanguines. L’avantage de cette méthode est que la fraction cellulaire retenue peut être analysée morphologiquement à l’aide de marqueurs épithéliaux, tels que les cytokératines mais aussi par une analyse moléculaire (ADN ou ARN).

Poster JIB 34

November, 12th
ScreenCell sponsors World CTC USA, November 12-15 2013, Boston Info+

  • Critically Evaluate the Latest Technology
  • Demonstrate Clinical Utility
  • Personalize Patient Car

2.30 pm: 3D Nuclear Telomere Parameters Define CTC Sub-populations

Sabine MaiProfessor, University of Manitoba

  • Introduction to the 3D telomere platform for cancer diagnosis
  • Overview of quantitative software (TeloView and TeloScan)
  • 3D telomeric profiles of CTCs isolated using the ScreenCell device


September, 25th
ISMRC 9th International Symposium on Minimal Residual Cancer, September 25-27 2013, Paris Info+

Poster presentation: Dr Naoual Benali, R&D Manager ScreenCell

Ex-vivo Expansion of CTCs in Culture Isolated by Size from Patients with Melanoma

Poster ISRMC JW 24 09 2013


February, 13th
ScreenCell sponsors TriCON 2013 from Feb 13-15 in San Francisco Info+

Sarah P. Thayer, M.D., Ph.D. / Associate Professor of Surgery; W. Gerald Austen Scholar in Academic Surgery; Director, Pancreatic Biology Laboratory / Massachusetts General Hospital

The capture, growth and genetic analysis of CTC in PDAC: What can it tell us about this disease?

CTC captured by ScreenCell devices were detected in patients with resectable PDAC.  These CTC are capable of in-vitro growth confirming tumorigenicity.  Selective deep sequencing demonstrated the feasibility of identifying mutations present in the primary tumor and their corresponding CTC.


Cambridge Healthtech Institute’s Third Annual Circulating Tumor Cells

Expediting Clinical Use

Part of the Twentieth Annual Molecular Medicine Tri-Conference
February 13-15, 2013 | Moscone North Convention Center | San Francisco, CA


November, 12th
ScreenCell sponsors the World CTC Summit in Boston (November 12-15 2012 – Hyatt Regency) Info+

On November 13th at 2pm, ScreenCell will host a presentation from :

Sabine Mai, Ph.D.
Senior Investigator, Manitoba Institute of Cell Biology,
Professor, University of Manitoba ,
Director, The Genomic Centre for Cancer Research and Diagnosis.


Dr Mai, will present 3D Nuclear Telomere Parameters Define CTC Subpopulations :

  • Introduction to the 3D telomere platform for cancer diagnosis
  • Overview of quantitative software (TeloView and TeloScan)
  • Outline of data obtained with CTCs isolated using the ScreenCell device

June, 18th
ScreenCell participates to Bio Boston from June 18th to 21st Info+

Boston Convention & Exhibition Center

415, Summer Street  Boston, MA 02210, Etats-Unis

HALL  A – Booth : 1043

April, 25th
ScreenCell sponsors Berlin’s CTC Summit on April 25th and 26th 2012 Info+

ScreenCell sponsors Berlin’s CTC Summit and will host a presentation from :

Sabine Mai, Ph.D.
Senior Investigator, Manitoba Institute of Cell Biology,
Professor, University of Manitoba ,
Director, The Genomic Centre for Cancer Research and Diagnosis.


Dr Mai, will present 3D Nuclear Telomere Parameters Define CTC Subpopulations :

  • Introduction to the 3D telomere platform for cancer diagnosis
  • Overview of quantitative software (TeloView and TeloScan)
  • Outline of data obtained with CTCs isolated using the ScreenCell device

February, 21st
ScreenCell sponsors TriCON 2012 from Feb 21st to 23rd in San Francisco Info+

Molecular Med TriCON 2012
February 19-23, 2012
Moscone North Convention Center, San Francisco, CA (USA)